GE HealthCare Technologies Inc. (GEHC) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q4 25	$1.4	$1.44	+2.9%	—	$5.7B	—
Q3 25	$1.05	$1.07	+1.9%	—	$5.1B	—
Q2 25	$0.92	$1.06	+15.2%	—	$5B	—
Q1 25	$0.91	$1.01	+11.0%	—	$4.8B	—
Q4 24	$1.26	$1.45	+15.1%	—	$5.3B	—
Q3 24	$1.05	$1.14	+8.6%	—	$4.9B	—
Q2 24	$0.98	$1	+2.0%	—	$4.8B	—
Q1 24	$0.91	$0.9	-1.1%	—	$4.7B	—
Q4 23	$1.07	$1.18	+10.3%	—	$5.2B	—
Q3 23	$0.9	$0.99	+10.0%	—	$4.8B	—
Q2 23	$0.87	$0.92	+5.7%	—	$4.8B	—
Q1 23	$0.79	$0.85	+7.6%	—	$4.7B	—
Q4 22	$1.06	$1.21	+14.2%	—	$4.9B	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$4.56	—	—	$20.6B	—
FY24	—	$4.37	—	—	$19.7B	—
FY23	—	$3.05	—	—	$19.6B	—
FY22	—	$4.63	—	—	$18.3B	—
FY21	—	$4.94

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$16.6B	$17.2B	$17.6B	$18.3B	$19.6B	$19.7B	$20.6B
YoY change	—	+3.19%	+2.45%	+4.3%	+6.6%	+0.61%	+4.84%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	16.6B	17.2B	17.6B	18.3B	19.6B	19.7B	20.6B
Cost of revenue	10.1B	10.4B	10.4B	11.2B	11.6B	11.5B	12.4B
Gross profit	6.5B	6.8B	7.2B	7.2B	7.9B	8.2B	8.2B
Gross margin	39.4%	39.4%	40.8%	39.1%	40.5%	41.7%	40%
Research & development	833M	810M	816M	1B	1.2B	1.3B	1.3B
Selling, general & administrative	3.6B	3.2B	3.6B	3.6B	4.3B	4.3B	4.2B
Operating expenses	4.4B	4B	4.4B	4.7B	5.5B	5.6B	5.5B
Operating income	2.1B	2.7B	2.8B	2.5B	2.4B	2.6B	2.8B
Operating margin	12.8%	15.8%	15.9%	13.8%	12.5%	13.3%	13.4%
Non-operating income, net	19M	7M	86M	76M	442M	462M	404M
Pretax income	2.1B	2.7B	2.9B	2.5B	2.4B	2.6B	2.8B
Income tax	410M	652M	600M	563M	743M	531M	614M
Net income	1.6B	13.9B	2.3B	2B	1.6B	2B	2.2B
Net margin	9.34%	81%	13%	10.7%	8.25%	10.4%	10.4%
EBITDA	2.8B	3.4B	3.5B	3.2B	3.5B	3.7B	3.7B
EPS	3.35	30.5	4.94	4.63	3.05	4.37	4.56
Diluted EPS	3.35	30.5	4.94	4.63	3.03	4.34	4.55

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	4.8B	5.2B	4.7B	4.8B	4.9B	5.3B	4.8B	5B	5.1B	5.7B	5.1B	5.3B
Cost of revenue	2.9B	3B	2.7B	2.8B	2.8B	3B	2.8B	3B	3.2B	3.4B	3.2B	3.1B
Gross profit	1.9B	2.2B	1.9B	2B	2B	2.3B	2B	2B	2B	2.3B	2B	2.2B
Gross margin	40.1%	41.4%	40.9%	41.4%	41.7%	42.8%	42.1%	39.7%	38.7%	39.7%	38.5%	41.2%
Research & development	322M	315M	324M	327M	316M	344M	344M	302M	292M	323M	345M	323M
Selling, general & administrative	996M	1.2B	1B	1.1B	1B	1.1B	1B	1B	1B	1.1B	1.1B	1.1B
Operating expenses	1.3B	1.5B	1.4B	1.4B	1.4B	1.5B	1.4B	1.3B	1.3B	1.4B	1.5B	1.4B
Operating income	617M	689M	540M	608M	676M	801M	628M	654M	653M	827M	515M	738M
Operating margin	12.8%	13.2%	11.6%	12.6%	13.9%	15.1%	13.1%	13.1%	12.7%	14.5%	10%	13.9%
Non-operating income, net	151M	44M	109M	101M	106M	144M	174M	66M	90M	74M	87M	60M
Pretax income	636M	609M	512M	578M	658M	834M	692M	613M	643M	821M	505M	693M
Income tax	250M	193M	124M	143M	168M	96M	104M	113M	179M	219M	94M	119M
Net income	382M	416M	388M	435M	490M	738M	588M	500M	464M	602M	411M	573M
Net margin	7.92%	7.99%	8.34%	8.99%	10.1%	13.9%	12.3%	9.99%	9.02%	10.6%	8.01%	10.8%
EBITDA	927M	884M	798M	858M	931M	1.1B	842M	874M	902M	1.1B	755M	967M
EPS	0.82	—	0.82	0.94	1.03	1.58	1.23	1.06	0.98	1.29	0.85	1.24
Diluted EPS	0.82	—	0.81	0.93	1.02	1.57	1.23	1.06	0.98	1.29	0.85	1.24

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	—	—	—	24.2B	35.2B	35.7B	37.4B	30.4B
Enterprise value	—	—	—	31.4B	42.5B	42.2B	43.4B	38.8B
Shares outstanding	454.7M	454.7M	454.7M	413.8M	455M	456M	456M	456M

Valuation

Metric	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	—	—	—	12.3	21.8	17.4	17.4	15.3
P/S	—	—	—	1.32	1.8	1.81	1.81	1.42
P/B	—	—	—	2.52	4.81	4.12	3.53	2.73
EV/EBITDA	—	—	—	9.7	12.1	11.5	11.8	10.8
EV/Sales	—	—	—	1.71	2.18	2.14	2.1	1.82
Earnings yield	—	—	—	8.14%	4.59%	5.75%	5.76%	6.54%
FCF yield	—	—	—	7.46%	4.87%	4.35%	4.02%	5.18%
PEG	—	—	—	—	—	—	—	0.9

Profitability

Metric	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	39.4%	39.4%	40.8%	39.1%	40.5%	41.7%	40%	41.2%
Operating margin	12.8%	15.8%	15.9%	13.8%	12.5%	13.3%	13.4%	15%
Net margin	9.34%	81%	13%	10.7%	8.25%	10.4%	10.4%	9.33%
ROE	—	94.2%	13.6%	20.5%	22.1%	23.7%	20.3%	19.4%
ROA	—	57.4%	8.72%	7.14%	4.97%	6.2%	5.84%	5.13%
ROIC	—	14.5%	13.2%	11.7%	11.4%	13.8%	13%	10.7%
Return on tangible assets	—	-512%	-72.3%	-174.5%	39.6%	44%	28.1%	62.7%

Financial health

Metric	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	—	0.9	1.04	1.16	1.05	1.04	1.37	1.26
Quick ratio	—	0.66	0.75	0.86	0.83	0.83	1.13	0.97
Debt / equity	—	0.03	0.03	0.9	1.35	1.08	0.99	0.94
Debt / assets	—	0.02	0.02	0.31	0.3	0.28	0.28	0.28
Net debt / EBITDA	—	-0.15	-0.03	2.23	2.1	1.77	1.62	2.29
Interest coverage	24.8	42.1	72.9	30.2	5.36	6.11	7.29	7.23
Effective tax rate	19.6%	24.1%	20.9%	22.4%	31.5%	20.6%	22.2%	23%

Per share

Metric	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	36.6	37.7	38.7	44.3	43	43.1	45.2	46.8
EPS (basic)	3.35	30.5	4.94	4.63	3.05	4.37	4.56	4.56
EPS (diluted)	3.35	30.5	4.94	4.63	3.03	4.34	4.55	4.34
Book value per share	—	32.4	37.2	23.2	16.1	19	23.2	24.3
FCF per share	3.65	3.14	2.99	4.36	3.77	3.4	3.3	3.48
Cash per share	—	2.19	1.22	3.48	5.48	6.3	9.85	4.6
Capex per share	0.46	0.49	0.51	0.74	0.85	0.88	—	—

Capital allocation

Metric	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	1.27%	1.29%	1.32%	1.67%	1.97%	2.04%	—	—
Capex / operating cash flow	12.3%	8.15%	10.4%	10.1%	11.5%	12.5%	—	—
Payout ratio	—	—	0%	0%	2.54%	2.68%	2.97%	3.23%
Dividend yield	—	—	—	0%	0.12%	0.15%	0.17%	0.24%

Yield

0.24%

trailing twelve months

Frequency

Quarterly

Last dividend

$0.04

ex-dividend Oct 23, 2026

Payout ratio

of earnings

Dividend growth

2 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
Oct 23, 2026upcoming	$0.04
Jul 24, 2026	$0.035
Apr 2, 2026	$0.035
Jan 9, 2026	$0.035
Oct 24, 2025	$0.035
Jul 25, 2025	$0.035
Apr 25, 2025	$0.035
Jan 14, 2025	$0.035

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	994M	554M	1.4B	2.5B	2.9B	4.5B
Receivables	1.6B	3B	3.1B	3.3B	3.4B	3.7B
Inventory	1.6B	1.9B	2.2B	2B	1.9B	2.2B
Total current assets	5.9B	7B	8.3B	9.4B	9.9B	12.5B
Property, plant & equipment	466M	479M	425M	544M	608M	951M
Goodwill & intangibles	26.9B	29.5B	28.7B	28.4B	28.4B	29.2B
Total assets	24.2B	26.3B	27.5B	32.5B	33.1B	36.9B
Accounts payable	2.2B	2.5B	2.9B	2.9B	3B	3.3B
Short-term debt	132M	110M	119M	1.1B	1.6B	642M
Total current liabilities	6.5B	6.8B	7.2B	9B	9.6B	9.1B
Long-term debt	336M	327M	8.5B	8.7B	7.8B	9.8B
Total liabilities	9.5B	9.4B	17.9B	25.1B	24.4B	26.3B
Shareholders' equity	14.8B	16.9B	9.6B	7.3B	8.7B	10.6B
Total debt	468M	437M	8.6B	9.9B	9.4B	10.5B
Net debt	-526M	-117M	7.2B	7.4B	6.5B	6B

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	2.4B	—	—	—	—	—	—	—	4B	4.5B	2.3B	2.1B
Receivables	3.2B	—	—	—	—	—	—	—	3.5B	3.7B	3.5B	3.5B
Inventory	2.1B	—	—	—	—	—	—	—	2.3B	2.2B	2.4B	2.5B
Total current assets	9.5B	—	—	—	—	—	—	—	11.9B	12.5B	10.4B	10.5B
Property, plant & equipment	2.4B	—	—	—	—	—	—	—	819M	951M	940M	940M
Goodwill & intangibles	28.5B	—	—	—	—	—	—	—	29.2B	29.2B	33.9B	34B
Total assets	32.4B	—	—	—	—	—	—	—	36.1B	36.9B	37.1B	37.2B
Accounts payable	2.8B	2.9B	2.9B	2.8B	2.9B	3B	3.2B	3B	3B	3.3B	3.4B	3.2B
Short-term debt	7M	—	—	—	—	—	—	—	2.1B	642M	139M	133M
Total current liabilities	7.6B	—	—	—	—	—	—	—	10.1B	9.1B	8.5B	8.3B
Long-term debt	10.3B	—	—	—	—	—	—	—	8.6B	9.8B	10.4B	10.4B
Total liabilities	25.1B	—	—	—	—	—	—	—	25.9B	26.3B	26.2B	26B
Shareholders' equity	7.3B	—	—	—	—	—	—	—	10.2B	10.6B	10.9B	11.2B
Total debt	10.3B	—	—	—	—	—	—	—	10.7B	10.5B	10.6B	10.5B
Net debt	7.9B	—	—	—	—	—	—	—	6.7B	6B	8.3B	8.5B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	1.7B	2.1B	2.3B	1.9B	1.6B	2B	2.2B
Depreciation & amortization	659M	630M	625M	633M	610M	580M	578M
Stock-based compensation	—	—	76M	67M	114M	125M	130M
Change in working capital	-512M	42M	-1.3B	-223M	-47M	2M	-153M
Operating cash flow	1.7B	2.7B	2.2B	3B	3.3B	3.2B	2B
Capital expenditure	-211M	-221M	-233M	-306M	-386M	-401M	—
Investing cash flow	-245M	-301M	-1.8B	-398M	-558M	-914M	-565M
Dividends paid	—	—	0	0	-41M	-55M	-64M
Share repurchases	—	—	—	—	—	—	-200M
Financing cash flow	-1.4B	-2.2B	-263M	-822M	-478M	-606M	580M
Net change in cash	37M	239M	214M	1.8B	2.3B	1.7B	2B
Free cash flow	1.7B	1.4B	1.4B	1.8B	1.7B	1.6B	1.5B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	386M	—	—	—	—	—	—	—	464M	602M	411M	574M
Depreciation & amortization	153M	—	—	—	—	—	—	—	148M	146M	153M	160M
Stock-based compensation	29M	—	—	—	—	—	—	—	38M	36M	35M	45M
Change in working capital	81M	—	—	—	—	—	—	—	-87M	328M	-70M	-437M
Operating cash flow	993M	193M	124M	143M	168M	96M	104M	112M	593M	1.1B	290M	168M
Capital expenditure	-80M	—	—	—	—	—	—	—	—	—	—	—
Investing cash flow	-99M	—	—	—	—	—	—	—	-38M	-135M	-2.3B	-15M
Dividends paid	-14M	—	—	—	—	—	—	—	-16M	-16M	-16M	-16M
Share repurchases	—	—	—	—	—	—	—	—	-100M	0	-100M	-200M
Financing cash flow	-24M	—	—	—	—	—	—	—	-168M	-306M	11M	-236M
Net change in cash	870M	193M	124M	143M	168M	96M	104M	112M	387M	609M	-2B	-83M
Free cash flow	570M	—	—	—	—	—	—	—	483M	916M	112M	68M

GE HealthCare Technologies Inc. Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement